Role of parp inhibitors in cancer immunotherapy: potential friends to immune activating molecules and foes to immune checkpoints

HIGHLIGHTS

SUMMARY

    PARPi have demonstrated to control the tumor immune microenvironment (TME) by modulating both cancer cell genomic instability and T_cell mediated responses. The authors have investigated additional unexplored mechanisms potentially elicited by PARP-1 inhibition that could provide support to the T_cell stimulation induced by ICIs, along with their intrinsic limitations. The influence of PARPi on anti-tumor T_cell immune_response and on TME features can be mediated by different mechanisms. Other released proteins include C-X-C motif chemokine ligand (CXCL)1, CXCL2, CXCL9, and CXCL10 that support both development and tumor infiltration of macrophages . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?